Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound ... obesity and moderate-to-severe obstructive sleep apnea, or OSA, a condition characterized by breathing ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

“This is the first pharmacologic therapy that can treat obstructive sleep apnea in this way,” says Dan Skovronsky, chief ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...